627 related articles for article (PubMed ID: 26392563)
1. Increased brain uptake of targeted nanoparticles by adding an acid-cleavable linkage between transferrin and the nanoparticle core.
Clark AJ; Davis ME
Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12486-91. PubMed ID: 26392563
[TBL] [Abstract][Full Text] [Related]
2. Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor.
Wiley DT; Webster P; Gale A; Davis ME
Proc Natl Acad Sci U S A; 2013 May; 110(21):8662-7. PubMed ID: 23650374
[TBL] [Abstract][Full Text] [Related]
3. Transcytosis of protein through the mammalian cerebral epithelium and endothelium. III. Receptor-mediated transcytosis through the blood-brain barrier of blood-borne transferrin and antibody against the transferrin receptor.
Broadwell RD; Baker-Cairns BJ; Friden PM; Oliver C; Villegas JC
Exp Neurol; 1996 Nov; 142(1):47-65. PubMed ID: 8912898
[TBL] [Abstract][Full Text] [Related]
4. Intracellular sorting and transcytosis of the rat transferrin receptor antibody OX26 across the blood-brain barrier in vitro is dependent on its binding affinity.
Haqqani AS; Thom G; Burrell M; Delaney CE; Brunette E; Baumann E; Sodja C; Jezierski A; Webster C; Stanimirovic DB
J Neurochem; 2018 Sep; 146(6):735-752. PubMed ID: 29877588
[TBL] [Abstract][Full Text] [Related]
5. Trafficking of Gold Nanoparticles Coated with the 8D3 Anti-Transferrin Receptor Antibody at the Mouse Blood-Brain Barrier.
Cabezón I; Manich G; Martín-Venegas R; Camins A; Pelegrí C; Vilaplana J
Mol Pharm; 2015 Nov; 12(11):4137-45. PubMed ID: 26440359
[TBL] [Abstract][Full Text] [Related]
6. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target.
Yu YJ; Zhang Y; Kenrick M; Hoyte K; Luk W; Lu Y; Atwal J; Elliott JM; Prabhu S; Watts RJ; Dennis MS
Sci Transl Med; 2011 May; 3(84):84ra44. PubMed ID: 21613623
[TBL] [Abstract][Full Text] [Related]
7. Antibody affinity and valency impact brain uptake of transferrin receptor-targeted gold nanoparticles.
Johnsen KB; Bak M; Kempen PJ; Melander F; Burkhart A; Thomsen MS; Nielsen MS; Moos T; Andresen TL
Theranostics; 2018; 8(12):3416-3436. PubMed ID: 29930740
[No Abstract] [Full Text] [Related]
8. Nanoparticle accumulation and transcytosis in brain endothelial cell layers.
Ye D; Raghnaill MN; Bramini M; Mahon E; Åberg C; Salvati A; Dawson KA
Nanoscale; 2013 Nov; 5(22):11153-65. PubMed ID: 24077327
[TBL] [Abstract][Full Text] [Related]
9. Study of the transcytosis of an anti-transferrin receptor antibody with a Fab' cargo across the blood-brain barrier in mice.
Manich G; Cabezón I; del Valle J; Duran-Vilaregut J; Camins A; Pallàs M; Pelegrí C; Vilaplana J
Eur J Pharm Sci; 2013 Jul; 49(4):556-64. PubMed ID: 23748097
[TBL] [Abstract][Full Text] [Related]
10. Transferrin receptors-targeting nanocarriers for efficient targeted delivery and transcytosis of drugs into the brain tumors: a review of recent advancements and emerging trends.
Choudhury H; Pandey M; Chin PX; Phang YL; Cheah JY; Ooi SC; Mak KK; Pichika MR; Kesharwani P; Hussain Z; Gorain B
Drug Deliv Transl Res; 2018 Oct; 8(5):1545-1563. PubMed ID: 29916012
[TBL] [Abstract][Full Text] [Related]
11. Enhancing Glioblastoma-Specific Penetration by Functionalization of Nanoparticles with an Iron-Mimic Peptide Targeting Transferrin/Transferrin Receptor Complex.
Kang T; Jiang M; Jiang D; Feng X; Yao J; Song Q; Chen H; Gao X; Chen J
Mol Pharm; 2015 Aug; 12(8):2947-61. PubMed ID: 26149889
[TBL] [Abstract][Full Text] [Related]
12. Development of antibody-modified chitosan nanoparticles for the targeted delivery of siRNA across the blood-brain barrier as a strategy for inhibiting HIV replication in astrocytes.
Gu J; Al-Bayati K; Ho EA
Drug Deliv Transl Res; 2017 Aug; 7(4):497-506. PubMed ID: 28315051
[TBL] [Abstract][Full Text] [Related]
13. Revisiting nanoparticle technology for blood-brain barrier transport: Unfolding at the endothelial gate improves the fate of transferrin receptor-targeted liposomes.
Johnsen KB; Moos T
J Control Release; 2016 Jan; 222():32-46. PubMed ID: 26658072
[TBL] [Abstract][Full Text] [Related]
14. The protein corona hampers the transcytosis of transferrin-modified nanoparticles through blood-brain barrier and attenuates their targeting ability to brain tumor.
Xiao W; Wang Y; Zhang H; Liu Y; Xie R; He X; Zhou Y; Liang L; Gao H
Biomaterials; 2021 Jul; 274():120888. PubMed ID: 34029915
[TBL] [Abstract][Full Text] [Related]
15. Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants.
Bien-Ly N; Yu YJ; Bumbaca D; Elstrott J; Boswell CA; Zhang Y; Luk W; Lu Y; Dennis MS; Weimer RM; Chung I; Watts RJ
J Exp Med; 2014 Feb; 211(2):233-44. PubMed ID: 24470444
[TBL] [Abstract][Full Text] [Related]
16. Brain uptake of multivalent and multi-specific DVD-Ig proteins after systemic administration.
Karaoglu Hanzatian D; Schwartz A; Gizatullin F; Erickson J; Deng K; Villanueva R; Stedman C; Harris C; Ghayur T; Goodearl A
MAbs; 2018 Jul; 10(5):765-777. PubMed ID: 29771629
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and brain uptake of lactoferrin in rats.
Ji B; Maeda J; Higuchi M; Inoue K; Akita H; Harashima H; Suhara T
Life Sci; 2006 Jan; 78(8):851-5. PubMed ID: 16165165
[TBL] [Abstract][Full Text] [Related]
18. Standardized Preclinical
Morrison JI; Petrovic A; Metzendorf NG; Rofo F; Yilmaz CU; Stenler S; Laudon H; Hultqvist G
Mol Pharm; 2023 Mar; 20(3):1564-1576. PubMed ID: 36808999
[TBL] [Abstract][Full Text] [Related]
19. Mathematical PKPD and safety model of bispecific TfR/BACE1 antibodies for the optimization of antibody uptake in brain.
Gadkar K; Yadav DB; Zuchero JY; Couch JA; Kanodia J; Kenrick MK; Atwal JK; Dennis MS; Prabhu S; Watts RJ; Joseph SB; Ramanujan S
Eur J Pharm Biopharm; 2016 Apr; 101():53-61. PubMed ID: 26820920
[TBL] [Abstract][Full Text] [Related]
20. Human Immortalized Cell-Based Blood-Brain Barrier Spheroid Models Offer an Evaluation Tool for the Brain Penetration Properties of Macromolecules.
Kitamura K; Okamoto A; Morio H; Isogai R; Ito R; Yamaura Y; Izumi S; Komori T; Ito S; Ohtsuki S; Akita H; Furihata T
Mol Pharm; 2022 Aug; 19(8):2754-2764. PubMed ID: 35766901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
